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Available online 14 May 2016AbstractTGF-b1 is involved in many aspects of tissue development and homeostasis including hematopoiesis. The TAL1 transcription factor is also
an important player of this latter process and is expressed very early in the myeloid and erythroid lineages. We previously established a link
between TGF-b1 signaling and TAL1 by showing that the cytokine was able to induce its proteolytic degradation by the ubiquitin proteasome
pathway. In this manuscript we show that TAL1 interacts with SMAD3 that acts in the pathway downstream of TGF-b1 association with its
receptor. TAL1 expression strengthens the positive or negative effect of SMAD3 on various genes. Both transcription factors activate the
inhibitory SMAD7 factor through the E box motif present in its transcriptional promoter. DNA precipitation assays showed that TAL1 present in
Jurkat or K562 cells binds to this SMAD binding element in a SMAD3 dependent manner. SMAD3 and TAL1 also inhibit several genes
including ID1, hTERT and TGF-b1 itself. In this latter case TAL1 and SMAD3 can impair the positive effect exerted by E47. Our results indicate
that TAL1 expression can modulate TGF-b1 signaling by interacting with SMAD3 and by increasing its transcriptional properties. They also
suggest the existence of a negative feedback loop between TAL1 expression and TGF-b1 signaling.
© 2016 The Authors. Published by Elsevier B.V. on behalf of Socie´te´ Franc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TAL1 (T-cell acute lymphoblastic leukemia protein 1), also
known as SCL (stem cell leukemia) is a tissue-specific tran-
scription factor belonging to the basic helix-loop-helix
(bHLH) family which dimerizes with other bHLH E factors
and binds E-box consensus motifs. By associating with DNA
directly or indirectly through interactions with other tran-
scription factors, TAL1 can act either positively or negatively
on transcription of specific genes. This has been well-
illustrated by systematic approaches characterizing the
various TAL1 targets [1e3]. In the case of a positive action it
has been shown that TAL1 can intervene in multiprotein* Corresponding author. Tel.: þ33 472728563; fax: þ33 472728080.
E-mail address: pjalinot@ens-lyon.fr (P. Jalinot).
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2214-0085/© 2016 The Authors. Published by Elsevier B.V. on behalf of Socie´te´ Fra
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncomplexes by associating with the LIM-only proteins LMO1
and LMO2, as well as the GATA factors [4e8]. TAL1 has also
been shown to interact with the p300 coactivator through its
basic domain [9]. These molecular interactions, along with
others as with SP1 [10], can lead to transcriptional activation
by TAL1. However TAL1 can also act negatively [1e3] and it
has been reported that it binds to the mSin3A transcriptional
repressor, also through its basic domain [11]. Experiments in
mice have shown that TAL1 represses the E47/HEB activity in
thymocytes by inducing recruitment of mSin3A [12]. The
expression of TAL1 is restricted to specific cells and devel-
opment stages [13]. In particular it is expressed in early he-
matopoiesis and plays an important role in the generation of
the erythroid and myeloid lineages. In the T-cell lineage
expression of TAL1 is normally lost early in the differentiation
process, but its abnormal maintenance as a consequence of
chromosomal rearrangements or epigenetic activation isnc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open access
c-nd/4.0/).
70 J.-M. Terme et al. / Biochimie Open 2 (2016) 69e78commonly associated with T-cell acute lymphoblastic leuke-
mia (T-ALL) [14e16]. TAL1 expression in this context is
likely to play an important role as its suppression by RNA
interference in Jurkat cells has been shown to lead to prolif-
eration stop [2]. We have previously shown that TAL1 can be
regulated by extracellular cytokines as TGF-b1 which induces
its degradation through the ubiquitin proteasome pathway
[17]. Association of TGF-b1 with its receptors leads to
phosphorylation of the receptor-regulated SMADs SMAD2
and SMAD3 [18,19]. These factors can then associate with
SMAD4 and enter the nucleus. These complexes by associ-
ating with specific sequence elements regulate either posi-
tively or negatively many genes [20,21]. TGF-b1 is important
in many aspects of tissue homeostasis and in particular plays
an important role in hematopoiesis as TAL1 does [22]. It has a
regulatory role on hematopoietic stem cells (HSCs) and it is
also important for differentiation of the myeloid and endo-
thelial lineage. These effects involve SMAD3 as shown by
gene disruption experiments which have established a role of
this transcription factor in hematopoiesis [23].
In this manuscript we show that TAL1 can specifically bind
SMAD3 and potentiate its positive or negative effect on spe-
cific genes. By activating negative regulator of the pathway as
SMAD7 and inhibiting TGF-b1 expression itself, TAL1 and
SMAD3 counteracts the TGF-b1 pathway functioning. These
data together with previous observations are in favor of
negative feedback loops between TGF-b1 and TAL1.
2. Materials and methods2.1. ConstructsPlasmids used in this study have been previously described:
pSGF-TAL1 [24], pSG5-MYC-TAL1 [25] and pSG-HA-Ub
[26]. pCMV-Flag-E47 was kindly provided by C. Gallego
[27]. pCDNA3-FLAG-SMAD2, -SMAD3 and eSMAD4 were
kindly provided by A. Favre-Bonvin.2.2. Cell culture and transfectionCell culture and transfection were performed as previously
described [24]. When indicated, cells were treated with human
platelet TGF-b1 (100 pM). To achieve inhibition of the pro-
teasome, MG132 (SigmaeAldrich, StLouis, USA) was added
at 10 mM for 4 h. Cellular extracts were normalized with
respect to protein concentrations which were quantified with
the DC protein assay kit (BioRad, Hercules, USA). HeLa cells
were stably-transfected with the pCEP-FLAG-TAL or the
control pCEP-FLAG-GFP constructs, as previously reported
[24].2.3. Immunoprecipitation and immunoblotTransfected cells were lysed in Nonidet P-40-
desoxycholate buffer (50 mM Tris pH 7.4, 150 mM NaCl,
1% Nonidet P-40, 0.5% Na desoxycholate, 0.5 mM Tris(2-
carboxyethyl)phosphine, and 0.5 mM Pefabloc).Immunoprecipitation were carried out by addition of anti-
bodies diluted 1:250 and incubation at 4 C for 1h30. Protein
A sepharose beads were added and incubated with the mix for
1 h. Beads were collected by centrifugation and washed three
times with Nonidet P-40-desoxycholate buffer. For experience
in Supplementary Fig. 1 protein G magnetic beads were used.
Proteins were eluted in 2 SDS sample buffer at 80 C for
10 min. After protein gel electrophoresis and transfer to PVDF
membrane, detection was carried out by incubation with pri-
mary antibodies diluted 1:1000 or as indicated by the manu-
facturer and revelation was performed by chemiluminescence
using ECL, ECL þ or ECL Prime kits. Following antibodies
were purchased: FLAG (clone M2, Sigma), MYC (clone
9E10, Sigma), HA (clone 12CA5, Roche), SMAD3 (NB600-
1258), SMAD2/3 (566412, Calbiochem) and TAL1 (BTL73,
Millipore).2.4. Luciferase assaysHeLa and 293T cells (1.4 105 cells) were transfected with
1.5 mg of constructs including the firefly luciferase coding
sequence under the control of various promoters: TGF-b1
[28], 3Tplux [29], CAGA boxes [30], hTERT [31], ID1 [32],
SMAD7-WT and SMAD7-mE [33] together with 15 ng of
thymidine kinase Renilla-luciferase (pRL-TK) by calcium
phosphate precipitation. Reporter gene analysis was performed
48 h after transfection by using the Dual-Luciferase™ Re-
porter Assay System (Promega, Madison, USA). The lucif-
erase activity associated with each construct was normalized
on the basis of pRL-TK activity. The values are those obtained
in triplicate, from one representative experiment (out of 3
experiments) and are represented with standard deviation. In
figures one, two and three stars indicate Student's T test (two
tail, unpaired) p-value less than 0.05, 0.01 and 0.001,
respectively.2.5. Real-time quantitative RT-PCRTotal RNAs were extracted from frozen cells using the
Rneasy mini-kit (Qiagen, Hilden, Germany). One step RT-
PCR reactions were performed using the QuantiTect™
SYBR Green RT-PCR kit (Qiagen) and the LightCycler
apparatus (Roche). Sequences of sense and antisense primers
were described previously [24].2.6. Nuclear extractsJurkat and K562 cells were grown in RPMI-1640 with 5%
fetal calf serum and treated with 781 pM TGF-b1 for 1 h. Cells
were collected by centrifugation, washed three times in PBS
1 and incubated for 30 min on ice in 3 pellet volumes of
hypotonic buffer (10 mM Hepes pH 7.9, 10 mM KCl, 1.5 mM
MgCl2, 0.1 mM EDTA pH 8.0, 0.1 mM EGTA, 1 mM DTT,
1 cOmplete™ mini EDTA-free protease inhibitor cocktail,
0.5 mM sodium vanadate). Cells were lysed using Dounce B
pestle and nuclei were collected by a 10 min centrifugation at
900 g. These nuclei were incubated for 15 min on ice in
71J.-M. Terme et al. / Biochimie Open 2 (2016) 69e78extraction buffer (20 mM Hepes pH 7.9, 360 mM NaCl,
1.5 mM MgCl2, 20% glycerol, 0.1 mM EDTA pH 8.0, 10
mMZnCl2, 1 mM DTT, 1 cOmplete™ mini EDTA-free
protease inhibitor cocktail, 0.5 mM sodium vanadate). Nu-
clear extracts corresponded to the supernatants after a 15 min
centrifugation at 12,000 g.2.7. DNA precipitation assaysFig. 1. Interaction between TAL1 and SMAD3: (A) 293T cells wereThe probe corresponding to the SMAD binding element
(SBE) of the human SMAD7 gene was obtained by hybridizing
a 50 biotinylated oligonucleotide (50- AGCGA-
CAGGGTGTCTAGACGGCCACGTGA -30) with another
corresponding to the complementary strand. Probe (0.25 mM)
was incubated in 160 ml with 100 mg of nuclear extracts,
polydIdC and 15 mM Tris pH 7.9, 3 mM MgCl2 and 0.2%
Triton X-100 (final concentration) for 15 min on ice. Strep-
tavidin magnetic beads were added and the mix was further
incubated for 15 min on ice. The magnetic beads were washed
three times in wash buffer (20 mM Tris pH 7.9, 50 mM KCl,
1.5 mM MgCl2, 10% glycerol, 0.1 mM EDTA pH 8.0, 10 mM
ZnCl2, 1 mM DTT, 1 cOmplete™ mini EDTA-free protease
inhibitor cocktail, 0.25% Triton X-100). For competition ex-
periments the mix was preincubated for 15 min on ice with
double stranded oligonucleotides corresponding to the
SMAD7 SBE wild type (50- CAGGGTGTCTAGACGGCCAC
- 30) or mutated (50- CAGGGTCATAGCGTGGCCAC - 30).
Proteins associated with DNA were eluted by heating the
beads for 10 min at 80 C in protein loading buffer and
analyzed by immunoblot after separation in 9% poly-
acrylamide SDS gel.
3. Resultstransfected with 2 mg of pSG5-MYC-TAL1 and either pCDNA3-FLAG-
SMAD2, -SMAD3 or -SMAD4 expression vectors as indicated. To avoid3.1. TAL1 interacts with SMAD3
possible TAL1 degradation cells were treated with the MG132 proteasome
inhibitor. Cell lysates were used for immunoprecipitation with an antibody to
FLAG. Immunoprecipitated proteins were analyzed by immunoblot using
antibodies to MYC (top panels) and to FLAG (bottom panel). (B) 293T cells
were transfected with pSG5-MYC-TAL1 either alone or in combination with
pCDNA3-FLAG-SMAD2 or eSMAD3 and treated with 100 pM of TGF-b1
during 9 h. Cellular extracts were normalized with respect to protein con-
centration and analyzed by immunoblot using antibodies to MYC (top panel)
or to b-actin as control (bottom panel). (C) 293T cells were transfected with
pSG5-MYC-TAL1, pCDNA3-FLAG-SMAD3 and pSG-HA-Ub as indicated.
Cell lysates were used for immunoprecipitation with an antibody to FLAG.
Immunoblot analysis was done using the antibody to HA (top panel) or to
MYC (bottom panel).As we have previously shown that the intracellular amount
of TAL1 was regulated by TGF-b1 [17], we investigated
further whether this transcription factor was able to interfere
with the TGF-b1 pathway through association with the SMAD
proteins which are tightly regulated by association of the
cytokine with its receptor. To test a possible direct binding of
TAL1 to these factors, 293 T cells were transfected with
vectors expressing SMAD2, SMAD3 and SMAD4 tagged with
the FLAG epitope, together with a construct producing TAL1
fused to the MYC epitope. These cells, as HeLa cells do not
express endogenous TAL1. These three SMADs were
expressed at similar levels as evaluated by an immunoblot
analysis of the cellular extracts (Fig. 1A, bottom panel).
Coexpression of the SMADs did not modify the level of MYC-
tagged TAL1 in the extracts (Fig. 1A, middle panel). Immu-
noprecipitation using the FLAG antibody showed a clear
coprecipitation of TAL1 with SMAD3 (Fig. 1A, top panel,
lane 3), but no association with SMAD2 or SMAD4 (Fig. 1A,
top panel, lanes 2 and 4). The SMAD3 signal was absent when
cells were transfected with the TAL1 or SMAD3 vector alone
as controls. To verify this interaction, the experiment was alsoperformed in the reverse way by precipitating an HA-tagged
form of TAL1 and detecting SMAD3. Similarly a clear and
specific binding of TAL1 to SMAD3 was observed
(Supplementary Fig. 1). These observations indicated that
TAL1 can bind SMAD3.
As we have previously shown that TGF-b1 was able to
induce polyubiquinylation and proteasome degradation of
TAL1 [17] we tested if coexpression of SMAD2 or SMAD3
affects this process. By treating cells transfected with the
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of TAL1 protein was observed in agreement with our previous
observations (Fig. 1B, top panel, compare lanes 1 and 4). This
effect was not modified by coexpression of either SMAD2 or
SMAD3 (Fig. 1B, top panel, lanes 2, 3, 5 and 6). The SMAD3
protein is also modified post-translationnally by poly-
ubiquitinylation [34]. This can be observed by transfecting
cells with a SMAD3 expression vector and a construct pro-
ducing ubiquitin tagged with the HA epitope. Immunoblot
analysis using the antibody to HA of immunoprecipitated
SMAD3 reveals a smear of polyubiquitinylated forms
(Fig. 1C, lane 6). This modification of SMAD3 is not affected
by coexpression of TAL1 (Fig. 1C, lanes 6 and 7).
These experiments show an interaction of TAL1 with
SMAD3 and that this binding does not interfere with the
modification by polyubiquitinylation of both proteins.3.2. TAL1 and SMAD3 cooperate in activation of TGF-
b1-induced genesFig. 2. TAL1 and SMAD3 transactivate TGF-b responsive promoter
sequence elements: HeLa cells were transfected with 300 ng of pSGF or
pSGF-TAL1, and 100 ng of pCDNA3 or pCDNA3-SMAD3, together with
1.5 mg of 3TPLux (A) and CAGA (B). Cell extracts were prepared 48 h after
transfection and analyzed for luciferase activity. The graph represents the
relative luciferase activity (mean of three points) and error bar corresponds to
standard deviation. P-values of a Student's T test are represented as described
in materials and methods.To investigate the functional relevance of this interaction
between TAL1 and SMAD3 we tested whether it affected the
activity of these transcriptional regulators. To this end cells
were transfected with constructs placing the luciferase reporter
gene under the control of sequence motifs of the human
plasminogen activator inhibitor-1 gene mediating transcrip-
tional activation by TGF-b1. These motifs corresponded to a
fragment of the PAI-1 gene (3TPLux) or to CAGA boxes in
tandem. Overexpression of SMAD3 transactivated both con-
structs, as well as TAL1 but in this case to a much lesser extent
(Fig. 2A and B compare lanes 1, 2 and 3). Combination of
SMAD3 and TAL1 led to a higher transactivation showing that
both proteins were able to act synergistically (Fig. 2A and B,
lanes 4). To confirm that both proteins were able to coopera-
tively activate TGF-b1-responsive genes we tested a construct
associating luciferase and the SMAD7 transcriptional pro-
moter. SMAD7 expression is known to be induced by TGF-b1
and to downregulate signaling by this cytokine by causing
degradation of TGF-b receptor type I (TGFBR1). Both TAL1
and SMAD3 transactivate the SMAD7 promoter and associ-
ation of both proteins led to a further increase (Fig. 3A
compare lanes 1, 2, 3 and 4). Mutation of the E box of the
SMAD7 promoter led to a complete loss of the transactivation
by the TAL1 SMAD3 combination (Fig. 3A, lane 5).
Considering the sensitivity of the effect to a mutation of the
SMAD binding element in the SMAD7 transcriptional pro-
moter we tested whether association of both proteins on this
DNA sequence could be observed using endogenous proteins.
This was done by performing DNA precipitation assays using
a biotinylated probe corresponding to the SMAD7 SBE. Nu-
clear extracts were prepared from TGF-b1 treated Jurkat cells
which express endogenous TAL1. In these extracts expression
of both SMAD3 and TAL1 as a 34 kD protein can be detected
by immunoblot analysis (Fig. 3B, lane 1). Both proteins were
also detected in the proteins eluted from the DNA probe
(Fig. 3B, lane 4), whereas no signal was obtained when thisprobe was omitted in the incubation, indicating that these two
proteins did not bind non specifically to the magnetic beads
under these conditions (Fig. 3B, lane 3). These experiments
were also performed with an antibody recognizing both
SMAD3 and SMAD2. This was done with nuclear extracts of
Jurkat and K562 erythroid cells, these latter also expressing
endogenous TAL1. In these extracts the signals corresponding
to SMAD2 and SMAD3 were clearly detected, the relative
abundance of SMAD2 being higher in Jurkat (Fig. 3C, lanes 1
and 5). Interestingly after DNA precipitation only the SMAD3
signal was detected with extracts of both cell types (Fig. 3C,
lanes 4 and 6, upper panels). As with Jurkat, the TAL1 protein
Fig. 3. TAL1 cooperates with SMAD3 to induce the SMAD7 promoter: (A) HeLa cells were transfected with 300 ng of pSGF or pSGF-TAL1, and 100 ng of
pCDNA3 or pCDNA3-SMAD3, together with 1.5 mg of pSMAD7-WT (WT) or pSMAD7-mE which includes a mutated E-box motif. Analysis of luciferase
activity was performed as described in legend to Fig. 2. (B). DNA precipitation assay was carried out using the SMAD7 SBE probe and a nuclear extract of Jurkat
cells treated for 1 h with TGF-b1. Lane 1 corresponds to the direct loading of 10% of the extract and lane 2 to loading of a protein molecular weight marker
(MWM). Proteins recovered after DNA precipitation were loaded in lanes 3 and 4 but in lane 3 the DNA probe was omitted as a control of non-specific binding to
the beads. The upper and lower panels correspond to immunoblot analyses with the antibodies directed against SMAD3 and TAL1, respectively. The star on the left
indicates a non-specific signal. The depicted images correspond to the superposition of colorimetric and chemiluminescence acquisitions with a ChemiDoc Touch
Imaging System apparatus (BioRad, Hercules, USA). The molecular weights of the marker bands are indicated on the left. (C). The DNA precipitation experiment
was carried out as in B with nuclear extracts of K562 (lanes 1 to 4) or Jurkat cells (lanes 5 to 6) and SMAD revelation was done using an antibody recognizing both
SMAD2 (upper band) and SMAD3 (lower band) as indicated. The immunoblots were also revealed with the monoclonal antibody to TAL1 (lower panels). Lanes 1
and 5 correspond to direct loading of the extract. In lane 3 the DNA probe was omitted as control. (D) The DNA precipitation assay was performed with a nuclear
extract of TGF-b1-treated K562 cells and the results are shown as in B. Lane 1 corresponds to 10% of this extract. In lanes 3 to 6 the nuclear extract was
preincubated with a 4 or 20 excess of double stranded oligonucleotides corresponding to the SBE wild type (SBE) or mutated (SBEm) as indicated. The
molecular weight marker was loaded in lane 7 and the molecular weights of the bands are indicated on the right.
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(Fig. 3C, lanes 4 and 6, lower panels). To check that the TAL1
binding was specific of SMAD3 we performed competition
experiment with a 4 and 20 excess of double stranded
oligonucleotide corresponding to the SBE. This was done with
nuclear extracts of K562 cells and sequences corresponding to
wild type or mutated SBE. At 20 excess a clear reduction of
the SMAD3 signal was seen with the wild type SBE oligo-
nucleotide but not with the mutated one (Fig. 3D, compare
lanes 5 and 6, upper panel). As compared to the mutated one,
the wild type SBE oligonucleotide also reduced the TAL1
signal (Fig. 3D, lanes 5 and 6, lower panel). This shows that
impairment of SMAD3 binding also affects TAL1 detection
indicating that a SMAD3-TAL1 complex binds and activates
the SMAD7 SMAD responsive promoter.3.3. TAL1 and SMAD3 can also cooperate in down-
regulation of cellular genesTAL1 has been described as a transcriptional activator, but
also as a transcriptional repressor. Such a negative effect was
observed in particular by testing a limited series of genes in a
cell line constitutively expressing TAL1 from an episomic
EBV derived vector. Using this tool two cell lines were
generated expressing either GFP, as a control, or TAL1 as
previously reported [24]. In these constructs both proteins
were tagged with the FLAG epitope. Quantitative real time
PCR analysis of several genes expression level between these
two cell lines showed that TAL1 was able to repress expres-
sion of IkBa and also of the ID1, ID2 and ID3 genes (Fig. 4A)
which are known to be R-SMAD sensitive. By contrast
Fig. 4. ID1 promoter repression by TAL1 and SMAD3: (A) HeLa cells were
stably-transfected with the pCEP-FLAG-TAL1 or the control pCEP-FLAG-GFP
constructs. After selection of stably-transfected cells, total RNAs were prepared
and analyzed by real-time quantitative RT-PCR for expression of various genes
as indicated. The amount of mRNAs are expressed as a ratio FLAG-TAL1 cells
versus FLAG-GFP cells. (B) Immunoblot analyses of cells transfected with
pCEP-FLAG-GFP (lane 1) or pCEP-FLAG-TAL1 (lane 2) using antibodies to
FLAG. (C) HeLa cells were transfected with 150 ng of pSGF (lanes 1 and 3) or
pSGF-TAL1 (lanes 2 and 4), and 100 ng of pCDNA3 (lanes 1 and 2) or
pCDNA3-SMAD3 (lanes 3 and 4), together with 1.5 mg of pID1-Luc. Analysis
of luciferase activity was performed as described in legend to Fig. 2.
Fig. 5. Repression of the hTERT promoter by TAL1 and SMAD3: HeLa
cells were transfected with 300 ng of pSGF (lanes 1 to 3) or pSGF-TAL1
(lanes 4 to 6), 100 and 50 ng of pCDNA3 (lanes 1, 4 and 2, 5) and 50 or
100 ng of pCDNA3-SMAD3 (lanes 2, 5 and 3, 6), together with 1.5 mg of
pGL3-hTERT-3300. Analysis of luciferase activity was performed as
described in legend to Fig. 2.
74 J.-M. Terme et al. / Biochimie Open 2 (2016) 69e78expression of the b-actin, cyclin B1, lamin, E47, ATM, ATF,
p16, p21 and HPI-a genes which have not been described as
responding to TGF-b was not affected by the presence of
TAL1. Immunoblot analysis using the antibody to FLAGshowed that both proteins were expressed at a similar level
(Fig. 4B, compare lanes 1 and 2). The TAL1 negative effect
was also observed in transient expression studies using a
construct including the luciferase reporter gene under the
control of the ID1 transcriptional promoter (Fig. 4C, compare
lanes 1 and 2). Interestingly SMAD3 was also able to repress
the ID1 promoter and coexpression of both TAL1 and SMAD3
led to a stronger effect (Fig. 4C, lanes 3 and 4). We previously
reported that TAL1 was able to negatively regulate the pro-
moter of the protein subunit of the telomerase enzyme [25]. By
testing the effect of SMAD3 on the hTERT promoter we also
observed a dose dependent negative effect (Fig. 5, compare
lanes 1, 2 and 3). Coexpression of TAL1 also reinforced this
negative effect of SMAD3 (Fig. 5, lanes 5, 6).
Finally as SMAD3 is known to be a negative regulator of
the TGF-b1 promoter we also investigated the TAL1 effect on
this transcriptional regulatory element. TAL1 was observed to
down regulate the TGF-b1 promoter (Fig. 6A, compare lanes
1, 2 and 3) and also to counteract its activation by the type I
bHLH protein E47 (Fig. 6B). Indeed overexpression of E47
markedly increased the activity of this promoter, but coex-
pression of TAL1 impeded this effect in a dose dependent
manner (Fig. 6B, lanes 4, 5 and 6). By expressing a low
amount of TAL1 this negative effect on E47 transactivation
was not observed (Fig. 6C, lanes 2 and 3) but coexpression of
SMAD3 led to a clear impairment of the E47 effect (Fig. 6C,
lane 5). This clearly showed that the TAL1 SMAD3 complex
can negatively downregulate several genes, including TGF-b1
itself.
By combining these different observations it appears that
TAL1 and SMAD3 might play a clear role in a negative
feedback loop downregulating TGF-b1 signaling. Indeed by
activating SMAD7 and inhibiting TGF-b1 they are likely to
act negatively on this pathway. In addition we have previously
Fig. 6. TAL1repressesTGF-b1promoter: (A)HeLa cellswere transfectedwith
pSGF (lanes 1) or 300 ng and 600 ng of pSGF-TAL1 (lanes 2 and 3), together with
1.5 mg of pTGFb1-1132-luc (B) HeLa cells were transfected with pSGF (lanes 1
and 4) or 300 ng and 600 ng of pSGF-TAL1 (lanes 2 and 3, 5 and 6), together with
150 ng of pCMV(lanes 1 to 3) or pCMV-E47 (lanes 4 to 6) and 1.5 mg of pTGFb1-
1132-luc. (C) HeLa cells were transfected with 50 ng of pSGF or pSGF-TAL1,
50 ng of pCMV or pCMV-E47, 75 ng of pCDNA3 or pCDNA3-SMAD3 as
indicated, together with 1.5 mg of pTGFb1-1132-luc. For all three panels analyses
of luciferase activity were performed as described in legend to Fig. 2.
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through AKT activation. This shows that TAL1 in combination
with SMAD3 could act negatively on key factors of the TGF-
b1 pathway (Fig. 7).
4. Discussion
Both TAL1 and TGF-b1 have been established as important
regulators of embryonic hematopoiesis. This is in particular
illustrated by knock-out experiments in mice. TAL1-deficient
mice indeed die around E9.5, with defects of hematopoietic
and endothelial cell lineages [35,36]. Targeted disruption of
the TGF-b1 gene also results in lethality at E10.5 in about
50% of mice with defective hematopoiesis and yolk sac vas-
culogenesis, transient survival of other mice being interpreted
as a consequence of maternal transfer of the cytokine [22,37].
Unexpectedly our results indicate a link between the events
downstream of TGF-b1 binding to its receptor and TAL1.
Indeed analysis of the interaction of TAL1 with the SMADs
mediating the TGF-b1 effect showed a specific binding of
TAL1 to SMAD3. Both TAL1 and SMAD3 have been
described to be regulated by polyubiquitinylation and protea-
some degradation [17,34]. From our observations this post
translational modification does not seem to be affected by
interaction between both proteins. In particular the over-
expression of SMAD3 does not modify the TGF-b1-induced
degradation of TAL1 that we previously reported [17]. From
a functional point of view, association between TAL1 and
SMAD3 results in an increase of their effect on specific
transcriptional targets, both in the case of a positive or a
negative action. Analysis of the sequences mediating TGF-b1-
activation of the human PAI-1 gene has shown the importance
of three CAGA boxes present in the promoter [38]. SMAD3
overexpression leads to activation of reporter constructs
bearing a PAI-1 TGF-b1 responsive element including this
motif [29] or multiple repeats of these CAGAs boxes [30] and
coexpression of TAL1 clearly potentiates this effect.
Conversely SMAD3 can downregulate several genes, as
hTERT or ID1, and TAL1 reinforces this effect. Such an
inhibitory effect of SMAD3 on ID1 has already been reported
[39], but appears to be cell-type dependent [40]. From the
limited number of genes tested in this study TAL1 and
SMAD3 seem to act in the same way and to potentiate their
mutual action on specific targets. Future systematic studies
performed in specific cell types should help to test more
extensively this overlap between TAL1 and SMAD3 targets.
As a first clue to this question we looked at the available
chromatin immunoprecipitation sequencing (ChIP-seq) data.
If many experiments have been performed with TAL1 and
SMAD3 we did not find ChIP-seq results performed with both
TAL1 and SMAD3 in the same cells in the presence of TGF-
b1. However Micrococcal Nuclease (MNase) ChIP-seq data
with both TAL1 and SMAD2/3 are reported in human em-
bryonic stem cells [41]. Hence we analyzed these data and
observed that several TAL1 and SMAD2/3 peaks overlap in a
number of genes (Supplementary Fig. 2). This can be observed
in the promoter region and also in the transcribed sequence.
Fig. 7. Crosstalk between TGF-b signaling pathways and TAL1: This
scheme recapitulates how TAL1 and SMAD3 act positively or negatively on
TGF-b1 target genes, this leading to a downregulation of TGF-b1 signaling
through SMAD7 and reduction of the cytokine expression. Conversely TGF-
b1 can lead to TAL1 degradation through AKT activation.
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involving both TAL1 and SMAD3. The list of the genes
showing combined TAL1-SMAD2/3 peaks is given in
Supplementary Table 1. Interestingly one the gene exhibiting a
combined TAL1/SMAD3 peak in its promoter, SKIL, codes
for a component of the SMAD pathway which binds to pro-
moters of TGF-b responsive genes and recruits a repressor
complex [42]. Two other genes belonging to this category code
for proteins also related to the SMAD pathway, ZCCHC14 is
indeed reported to interact with SMAD3 and ZZEF1 with
SKIL [43,44]. These data support the notion that TAL1 and
SMAD3 can co-regulate various genes. However this ChIP-seq
approach will have to be carried out in various conditions of
TGF-b1 treatment to increase the number of SMAD3 bindingpeaks to promoters which is relatively low in these
HUES64 cells. Depending on the cellular context as well as on
the presence of other partner factors in relation with the effect
of TGF-b1, the regulatory effects reported in this manuscript
might vary. However, as also supported by the MNase ChIP-
seq data mentioned, our experiments show that co-binding
of both TAL1 and SMAD3 to promoter sequences can be
clearly observed with the endogenous proteins of both
erythroid and leukemic lymphoid cells. Future detailed ana-
lyses will help to determine the exact contribution of the
SMAD3-TAL1 proteineprotein interaction and of DNA
binding of both transcription factors to promoter sequences.
Interestingly Dogan et al. have recently reported that binding
of both TAL1 and SMAD1 faithfully predicts the existence of
an enhancer element, in a better way that the presence of
specific epigenetic marks. Hence co-binding of both TAL1 and
SMAD3 is likely to be a good predictor of an active regulatory
element [45].
Our analysis of the transcriptional targets of SMAD3 and
TAL1 interestingly showed that both factors are likely to ret-
roact negatively on TGF-b1 signaling. SMAD7 is indeed well
established as a negative regulator of the TGF-b1 signaling by
impairing proper activation of the receptor-regulated SMAD2
and SMAD3 [46] or by triggering degradation of activated
TGFBR-I [47]. TAL1 and SMAD3 synergistically activate
expression of this inhibitory SMAD. Also analysis of the TGF-
b1 promoter itself indicates a negative effect of both factors. In
agreement with previous description of the negative effect of
TAL1 on E47 [12], expression of the former was observed to
impede the strong activation exerted by the latter on this
promoter and SMAD3 strengthened this effect. These obser-
vations indicate that both factors are likely to facilitate
termination of TGF-b1 signaling through these specific ac-
tions. As we previously showed that TGF-b1 causes degra-
dation of TAL1 by the ubiquitin-proteasome pathway through
AKT phosphorylation it appears that a negative feedback loop
is likely to exist between TGF-b1 and TAL1.
Hence in TAL1 expressing cells, in particular the pre-
cursors of the hematopoietic and endothelial lineages, the
action of TGF-b1 is probably restricted by the presence of this
tissue-specific bHLH factor. In this line we have observed the
SMAD3-TAL1 interaction on the SMAD7 SBE with
K562 cells extracts. Accordingly the well-established negative
effect of TGF-b1 on proliferation of HSC [22] might be
related to a downregulation of TAL1. It is interesting to
mention that SMAD3 gene targeted disruption mimics at least
to some extent the TGF-b1 effects on hematopoiesis [23],
showing a specific effect of this particular SMAD in these
cells. TGF-b1 restricts HSC proliferation, but is also important
for differentiation of these cells [22]. Our observations indi-
cate that this process might involve a fine tuning of the TGF-
b1 signaling by the level of TAL1 expression. It will be also
interesting to study this connection between TGF-b1 signaling
and TAL1 in the case of T-ALL as we have also observed its
binding to SMAD3 in such cells. TAL1 is an important factor
in many pediatric and adult T-ALL and mutations in the
77J.-M. Terme et al. / Biochimie Open 2 (2016) 69e78TGFBR1 receptor have been reported in some cases of T-ALL
[48]. Hence it will be interesting to decipher how both TAL1
and TGF-b1 intervene in various types of T-ALL cells.
In conclusion our observations establish a new and unan-
ticipated link between TAL1 and TGF-b1 through SMAD3.
These data along with the current knowledge on these proteins
incite to develop future studies to assess the importance of this
connection in hematopoiesis, as well as in T-cell leukemia
onset.
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